drugset
drugset / Trial / NCT06277934

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT06277934 ↗

Phase 2 Completed 73 enrolled Regor Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity

Timeline

Start
2024-03-08
Primary completion
2024-08-13
Completion
2024-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject RGT001-075 Small molecule — Oral

Indications

obesity disorder